Attovia Therapeutics CFO granted 140K stock options

Q: When do Steven Chan’s ATTO stock options vest?

Twenty-five percent vests on August 4, 2027. The remaining options vest in equal monthly installments over the following 36 months, subject to continued service through the vesting dates.

Twenty-five percent of the options vests on August 4, 2027, with the balance vesting monthly over the following 36 months, subject to continued service.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. Chief Financial Officer Steven Chan was granted stock options on August 4, 2026, covering 140,000 common shares at an exercise price of $17 per share. Twenty-five percent vests on August 4, 2027; the remainder vests in equal monthly installments over the following 36 months, subject to continued service through those dates. The options expire August 3, 2036. The amendment replaces the August 6, 2026 Form 4 in its entirety and reports no changes to Chan’s beneficial ownership.

Insider Trade Summary

Grant/Award: 140,000 shares

Grant/Award 1 txn

Insider Chan Steven

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	140,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 140,000 contracts (Direct)

Footnotes (1)

F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

Key Figures

Options granted: 140,000 options Exercise price: $17 per share Initial vesting portion: 25% +3 more

6 metrics

Options granted 140,000 options Awarded August 4, 2026; each option covers a common share.

Exercise price $17 per share Price to exercise the options.

Initial vesting portion 25% Vests August 4, 2027, subject to continued service.

Initial vesting date August 4, 2027 The first 25% of the options vests on this date, subject to continued service.

Remaining vesting period 36 months The remaining options vest in equal monthly installments, subject to continued service.

Option expiration date August 3, 2036 Expiration date for the options.

Key Terms

Stock Option (Right to Buy), exercise price, vest

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"25% of the options shall vest on August 4, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did ATTO CFO Steven Chan receive?

Steven Chan, Attovia Therapeutics’ Chief Financial Officer, received options covering 140,000 shares of common stock on August 4, 2026, with an exercise price of $17 per share.

When do Steven Chan’s ATTO stock options vest?

Twenty-five percent vests on August 4, 2027. The remaining options vest in equal monthly installments over the following 36 months, subject to continued service through the vesting dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/08/2026 - 08:00 PM EDT Accepted by SEC EDGAR 10/08/2026 - 08:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Steven

(Last)

(First)

(Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/06/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17	08/04/2026		A		140,000		⁽¹⁾	08/03/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

Remarks:

This Form 4 amendment amends the Form 4 filed on August 6, 2026, which reported the Reporting Person's beneficial ownership using the Issuer's CIK number. This Form 4 amendment has been filed under the Reporting Person's CIK and reflects him as the Reporting Person. This filing amends and replaces the original filing in its entirety. No changes have been made or are being reported with respect to the Reporting Person's beneficial ownership of the Issuer's securities.

	/s/ Steven Chan	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR